
Mountain roads and coal mines cut grizzly bears off from habitat, study finds
Analyzing 20 years worth of GPS collar data from over 100 grizzly bears, the research, published in Conservation Science and Practice, found that humans have had a significant impact on the way bears move across an 85,000 square kilometre landscape in southern B.C. and Alberta.
"There already has been quite a bit of connectivity loss for grizzly bears in the southern Canadian Rocky Mountains," said Eric Palm, the study's lead author and a postdoctoral researcher at the University of Montana.
Any new coal mines, towns or highway roads would create more barriers for grizzly bears to move around and find food, he said — potentially having bigger ramifications down the road.
"Since that baseline is already pretty high, any additional losses could eventually have population-level effects for grizzly bears," he said.
In January, the province lifted a moratorium on coal mining in the eastern slopes of the Rocky Mountains, opening the door for suspended projects to resume.
More human development on the horizon — like new and resuming coal mine projects — could further threaten bear habitats, Palm said.
"In B.C. and Alberta there are a lot of proposed coal mine expansions of existing mines, and then there are also some new mines that are being proposed," he said.
"Building new coal mines in each one of these areas … expands the footprint of human infrastructure [which] can affect connectivity by usually inhibiting animals moving from one habitat patch to another."
Looking for food, finding trouble
Using computer simulations to predict how more development will impact bears in the future, the study found that those habitat patches would be further disconnected, restricting movement.
Palm explained that grizzly bears in the Canadian Rockies rarely venture out into the prairies, staying confined to the mountains. But there, bears are more constrained, as humans typically develop infrastructure in valley bottoms where some food sources thrive.
The researchers found that when food was scarce, both male and female bears risked coming closer to roads to search for it with forest along roadsides being home to attractive foods such as grasses, flowering plants and buffaloberries.
Tal Avgar, a wildlife ecologist and assistant professor at the University of British Columbia who contributed to the study, said a "grizzly bear that wants to live a long and happy life needs to avoid humans as much as possible."
The most recent count in Alberta shows 235 grizzly bear mortalities were caused by humans in the period between 2013 and 2022. Most known grizzly bear deaths in the province are caused by humans.
In May, two female grizzly bears were killed by trains in separate incidents in Banff National Park.
"Sometimes humans are associated with where the food is, but in general, we know that bears would like to avoid being close to humans. They would like to avoid being on infrastructure used by humans," Avgar said.
A potential threat to bear populations
"If genes are being inhibited from flowing from one area… eventually some of these populations could become more isolated from each other," Palm speculated.
Though this study was limited in scope to the data on grizzly movements, Palm said there was room to further research the potential for new infrastructure to limit not just the bears' mobility, but also how that could impact their breeding.
Although the threat of new development is concerning, Palm said much work is being done to help increase habitat connectivity in the Rockies, such as wildlife crossings over or under roads that help animals move across human infrastructure.
"Now there is a lot of vulnerability between different species and how much they adopt using these crossings, and sometimes these crossings are very successful, and sometimes less so," Avgar said.
While wildlife crossings are still helpful in building habitat connections, Avgar said, that solution is limited to roads.
"There are definitely situations where we can't actually provide those crossing structures [such as] human settlement or a mine," he said. "We can't build a bridge above it. It's an area that the bears are going to avoid to some extent.
"The main thing that we need to keep in mind is that when we plan development, we want to plan it at the large landscape scale, keeping in mind that we still allow populations of animals to move across that landscape, and if we blocked one path, maybe leave other paths open for future development."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
4 hours ago
- National Post
Genentech and Roche Present New Insights in Alzheimer's Disease Research Across Its Diagnostics and Pharmaceutical Portfolios at AAIC
Article content – Trontinemab's Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative and ARIA-E remaining <5% – Article content – Design of the Phase III TRONTIER 1 and 2 studies of trontinemab in early symptomatic Alzheimer's disease featured, with initiation planned in 2025 – Article content Article content – Plans for new Phase III trial investigating trontinemab in preclinical Alzheimer's disease, in people at high risk of cognitive decline – Article content – New real-world data support Elecsys pTau217 as a standalone blood test, comparable to a PET scan, for rule-in and rule-out identification of amyloid pathology – Article content SOUTH SAN FRANCISCO, Calif. — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer's development portfolio is being presented at the Alzheimer's Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer's across the entire patient journey. Article content Featured oral presentations include the latest results from the ongoing Phase Ib/IIa Brainshuttle™ AD study, which continue to support rapid and robust reduction of amyloid plaques, and design of the Phase III TRONTIER 1 and 2 studies of investigational trontinemab for early symptomatic Alzheimer's disease, with initiation planned later this year. As part of its growing Alzheimer's development program, Roche announced today its plans for an additional Phase III trial to investigate trontinemab in preclinical Alzheimer's disease. The trial will focus on individuals at risk of cognitive decline, with the goal of potentially delaying or preventing the progression of the disease to symptomatic stages. Article content 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics,' said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. With plans for Phase III trials in both early symptomatic and preclinical Alzheimer's disease, we are advancing science with the goal of delaying—and ultimately preventing—progression of this devastating condition.' Article content Late-breaking oral and poster presentations highlight the potential of Roche's Elecsys ® pTau217 as a reliable and accessible blood-based biomarker test, providing comparable results to PET scan and cerebrospinal fluid (CSF) diagnostics for rule-in and rule-out diagnosis of amyloid pathology, a hallmark of Alzheimer's disease, across care settings. The test, which received Breakthrough Device Designation from the U.S. Food and Drug Administration last year, will also be utilized in Roche's TRONTIER studies. Article content 'Blood based testing for Alzheimer's disease has the potential to greatly improve patient access and decrease the time to definitive disease diagnosis,' said Matt Sause, CEO of Roche Diagnostics. 'Our data show that the Elecsys pTau217 test performs comparably to PET scans but can be performed with a simple blood draw and analyzed in a routine clinical laboratory. This has the potential to transform the diagnosis of Alzheimer's and provide clear answers to caregivers, patients, and their families.' Article content Up to 75% of people living with symptoms of Alzheimer's disease globally have not been diagnosed, and those who have, waited an average of 2.8 years, and even less have received any form of treatment. Diagnostics play a crucial role in addressing the global challenge of Alzheimer's, not only to detect and identify people with the disease early, even before the first symptoms, but also to rule out those who may or may not benefit from specific treatments. Article content Pharmaceuticals Article content In a 90-minute Featured Research session, designs were shared for the Phase III studies, TRONTIER 1 and 2, which will initiate later this year, investigating the efficacy and safety of investigational trontinemab in people with early Alzheimer's disease. The primary endpoint will measure the change in cognition and function based on the Clinical Dementia Rating – Sum of Boxes scale after 18 months of treatment. Secondary endpoints will include assessments of cognition, function, behavioral symptoms, and quality of life. A pre-screening study, TRAVELLER, based on a brief clinical assessment and a plasma biomarker, which will be identified using the Elecsys pTau217 test, has also been initiated, to enable broader community outreach and extend access to these trials to more diverse populations representative of Alzheimer's disease. Article content New data on the latest results for trontinemab from the completed dose-expansion part of the 1.8 mg/kg and 3.6 mg/kg cohorts from the ongoing Phase Ib/IIa Brainshuttle AD study continued to show rapid and robust reduction of amyloid plaques in the brain as measured by amyloid positron emission tomography (PET). In the 3.6 mg/kg cohort, trontinemab reduced amyloid levels below the 24 centiloid positivity threshold in 91% of participants (n=49/54) after 28 weeks of treatment; 72% (n=39/54) achieved deep clearance below 11 centiloids. Article content These data were reinforced by early and significant reductions in fluid biomarkers of Alzheimer's disease, including total tau, phosphorylated Tau (pTau)181, pTau217, and neurogranin measured in CSF and continues to show a favourable safety and tolerability profile. Amyloid-related imaging abnormalities-edema/effusion (ARIA-E) continued to be observed in <5% of participants (blinded data; N=4/149 across 1.8 and 3.6 mg/kg dose cohorts). All cases were radiographically mild, one was associated with mild and transient symptoms. Article content Diagnostics Article content Roche will present data on a new study comparing the pTau217/Ab42 plasma ratio to the high-throughput, fully automated Elecsys pTau217 assay. The presentation will report on the accuracy of these tools in detecting amyloid pathology. Together with the high throughput and full automation of the assay, these data will assess the potential of Elecsys pTau217 as an accurate standalone rule-in and rule-out test that could be scaled up for broad implementation in routine clinical practice worldwide. Article content Additionally, results from a cohort-based model of healthcare utilization in the U.S. demonstrated that using the Elecsys ® pTau181 blood-based rule-out test in primary care scenarios improved diagnostic accuracy and reduced resource use compared with the current standard-of-care clinical, cognitive and imaging tests. If made available in primary care settings, the Roche Elecsys ® pTau181 blood test has the potential to reliably avoid the need for further confirmatory testing in nearly all people who receive a negative result. This will avoid the need for these people to undergo unnecessary testing using CSF or PET, which often come with long wait times and high cost, resulting in further delays to diagnosis and cost to healthcare systems. Article content Medicine Abstract title Presentation number (type) Presentation date (session) Time Abstracts will be available on the AAIC website. Pharmaceuticals Next wave of innovation in Alzheimer's disease therapeutics: The value of novel active transport mechanisms Featured Research Session (FRS), Talk 1 Room 718 27 July 2025, 2pm – 3:30pm EDT Cath Mummery, Roberto Villaseñor, Jens Niewoehner, Scarlett Barker, Luka Kulic Latest results from the dose-expansion part (Part 2) of the Brainshuttle™ AD study of trontinemab in people with Alzheimer's disease Featured Research Session (FRS), Talk 2 Room 718 27 July 2025, 2pm – 3:30pm EDT Luka Kulic, Fabien Alcaraz, Gregory Klein, Stephen Salloway, Carsten Hofmann, João A. Abrantes, Stella Yilmaz, Denise Sickert, Maddalena Marchesi, Jakub Wojtowicz, Andres Schneider, Ruth Croney, David Agnew, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel Interim biomarker results for trontinemab, a novel Brainshuttle™ antibody in development for the treatment of Alzheimer's disease Featured Research Session (FRS), Talk 3 Room 718 27 July 2025, 2pm – 3:30pm EDT Gregory Klein, Gil Rabinovici, Henrik Zetterberg, Matteo Tonietto, Tobias Bittner, Daria Rukina, Fabien Alcaraz, Carsten Hofmann, Maddalena Marchesi, Jakub Wojtowicz, Ruth Croney, David Agnew, João A. Abrantes, Franziska Schaedeli Stark, Silke Ahlers, Paul Delmar, Hanno Svoboda, Iris Wiesel, Luka Kulic TRONTIER 1 and TRONTIER 2: Pivotal trials of trontinemab in early symptomatic Alzheimer's disease Featured Research Session (FRS), Talk 4 Room 718 27 July 2025, 2pm – 3:30pm EDT Janice Smith, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Reisa Sperling, Henrik Zetterberg, Angeliki Thanasopolou, Christopher Lane, Paul Delmar, Gregory Klein, Ruth Croney, Jakub Wojtowicz, Carsten Hofmann, Luka Kulic, Hideki Garren Diagnostics Evaluating the Impact on Diagnostic Performance and Healthcare Resource Utilization of Introducing a plasma rule-out test in the Alzheimer's Disease Diagnostic Pathway Poster #102729 27 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Gustaf Ortsäter, Joana Amorim Freire Location tbc Evaluating the Clinical Performance of the Elecsys pTau217 Plasma Immunoassay to Detect Amyloid Pathology in a Routine Clinical Practice Cohort Poster #96679 28 July 2025, 7:30am – 4:15pm EDT Sayuri Hortsch, Niels Borlinghaus, Alexander Jethwa, David Caley, Annunziata Di Domenico, Craig Ritchie Clinical performance and effect of pre-analytical variation of plasma pTau217 alone versus the plasma pTau217/Aβ42 ratio for the identification of amyloid pathology Oral Developing Topics #108585 3-23-DEV Developing Topics on Tau Biomarkers 29 July 2025, 2:00pm – 3:30pm EDT Christopher M. Rank, Joana Amorim Freire, Alexander Jethwa, Annunziata Di Domenico, Christina Rabe, Marc Suárez-Calvet, Colin L. Masters, Tobias Bittner Accuracy of cerebrospinal fluid biomarker ratios to determine amyloid positron-emission tomography status: a diagnostic test accuracy meta-analysis Poster #100941 28 July 2025, 7:30am – 4:15pm EDT Pablo Martinez-Lage, Eino Solje, Julian G. Martins, Sraboni Sarkar Equity in diagnosis through adequate clinical trial design in diagnostic performance studies Poster #102804 30 July 2025, 7:30am – 4:15pm EDT Imke Kirste, David Caley, Clara Quijano Rubio, Margherita Carboni Investigating Differences in Patients Enrolled in a Clinical Study Based on Referral Type Poster #108110 30 July 2025, 7:30am – 4:15pm EDT Sophie Roth, Laura Schlieker, Sayuri Hortsch, Joana Amorim Freire, David Caley Article content About trontinemab Article content Trontinemab is an investigational Brainshuttle bispecific 2+1 amyloid-beta targeting monoclonal antibody specifically engineered for enhanced access to the brain to enable rapid reduction of amyloid in people with Alzheimer's disease. Trontinemab is designed for the efficient transport across the blood-brain barrier to target aggregated forms of amyloid beta and remove amyloid plaques in the brain. Article content The uniqueness of trontinemab is based on Roche's proprietary Brainshuttle technology combining an amyloid beta-binding antibody with a transferring receptor (TfR1) shuttle module. As a result, high central nervous system (CNS) exposure of trontinemab may be achieved at low doses, leading to a rapid and deep amyloid clearance. Due to its unique properties, trontinemab might unlock the full potential of disease-modifying monoclonal antibodies by effectively penetrating the brain and potentially leading to slowing of disease progression. Article content About Roche in Alzheimer's Disease Article content With more than two decades of scientific research in Alzheimer's disease, Roche is working towards a day when we can detect and treat the disease early, in order to slow down, stop or even prevent its progression to preserve what makes people who they are. Today, the company's Alzheimer's disease portfolio spans investigational medicines for different targets, types and stages of the disease, including trontinemab. On the diagnostics side, it also includes approved and investigational tools, including digital and blood-based tests and CSF assays, aiming to more effectively detect, diagnose and monitor the disease. Yet the global challenges of Alzheimer's disease go well beyond the capabilities of science, and making a meaningful impact requires collaboration both within the Alzheimer's community and outside of healthcare. Roche will continue to work together with numerous partners with the hope to transform millions of lives. Article content About Genentech in Neuroscience Article content Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases. Article content Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer's disease, Huntington's disease, Parkinson's disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today. Article content Article content Article content Article content Article content


CTV News
20 hours ago
- CTV News
SuperNOVA summer camp: High school students get hands-on experience solving climate problems
High school students in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles to the test in the Halifax Harbour. Jarman Ley, the program coordinator of SuperNOVA, said 25 students took part in the program focused on ocean technologies, engineering, and artificial intelligence. 'We started this program to get high school students excited and interested in the climate and how the ocean relates to that,' said Ley. 'They all developed programs for their own sensors and then drove them into the harbour to see the difference between historical harbour data and current harbour data.' SuperNOVA Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic) The students are testing for oxygen, solidity, and the acidity of the water, said Ley. 'They are specifically doing dissolved oxygen to see if fish have enough oxygen to breathe. They are doing the solidity because as climate changes or temperature changes you can have saltier waters, which is inhospitable to plants. They are doing the acidity of the water, the oxygen reduction potential, which is essentially how the ocean cleans itself.' Ley said the program teaches skills the students can take into their university careers. 'It's been a really interesting way to take all of the knowledge that we've learned and wrap it into one project that we can test and see the results of,' said student Finnegan Jafmann. SuperNOVA Students participating in Dalhousie University's SuperNOVA Ocean Climate Innovation Program put their remotely operated vehicles into the Halifax Harbour Friday, July 25, 2025. (Paul DeWitt/CTV Atlantic) 'A lot of the people here are probably going to use this as really good experience because we got to go to a lot of places. We got to tour multiple parts of the Dal building and the engineering section, and we got to talk to a lot of people about their projects,' said student Emily Whidden. 'For me, it was a lot of interesting information, but for the people who are planning to go into these fields or even come to Dal, it was probably a really good foot in the door.' From 2023 to date, Dalhousie University said SuperNOVA has reached more than 27,500 youth through this not-for-profit initiative. 'Young people are the lifeblood of the future. So, we really believe if we start to encourage them now, that they'll be that much more advanced when they get to university and potentially study it and develop the next generation of innovation,' said Ley. According to Dalhousie University, SuperNOVA summer camps introduce participants to STEM concepts, careers and mentors through 'fun experiments and innovative hands-on activities.' For more Nova Scotia news, visit our dedicated provincial page


CBC
a day ago
- CBC
Clearcutting tied to 18-fold increase in flood risk: UBC study
Social Sharing A new study from the University of British Columbia suggests that clearcut logging can make catastrophic floods up to 18 times more frequent. The study, published in the Journal of Hydrology, analyzed long-term data from one of the world's longest-running forest research sites in North Carolina, the Coweeta Hydrologic Laboratory. "We had a good opportunity to test out the effect of the physical characteristics of the landscape on the relationship between logging practices and flooding," Younes Alila, a UBC hydrologist and senior author of the study, told CBC News. Researchers compared two neighbouring watersheds, one facing north, the other south, that were both clear-cut in the late 1950s. They found that clear-cutting in the north-facing watershed, which receives less sunlight and retains more moisture, had a dramatic effect on flood behaviour. WATCH | What are the lasting effects of B.C.'s logging? What are the lasting effects of B.C.'s logging? 12 months ago "The north-facing watershed was super sensitive," Alila said. In that watershed, average flood sizes increased by nearly 50 per cent, while the largest floods were 105 per cent bigger than they were before logging. "Different sides of the mountains will respond differently to logging," Alila explained. He says the north side receives less sunlight, which keeps the soil wetter year-round. When storms arrive, the ground is already moist and can't absorb much water, causing more rain to run off into streams and rivers, resulting in larger floods. In contrast, the south-facing watershed, which loses more moisture due to greater sunlight exposure, saw almost no change in flooding after clear-cutting. Visit a clearcut the size of a city in B.C.'s Interior 3 years ago Mike Morris is the MLA for Prince George-Mackenzie, a portion of the province that has historically been highly forestry-dependant and heavily logged. He is also a trapper who sees first-hand the impact of that logging on local wildlife, and he wants the rest of the province to know what it looks like. Correction: A previous version of the story included an estimation of the clear cut area that referred to the larger region, not the specific clearcut. Alila called the difference "a breakthrough finding," highlighting how landscape factors like the direction a slope faces can reshape a watershed's flood regime. "The point we are trying to make is that we can use the way Mother Nature designed the landscape … to better manage the forest in ways that minimize the risk to hydrology and the risk of floods." Precautionary approach In addition to slope orientation, the hydrology professor emphasized that other landscape characteristics, including whether the terrain is flat or mountainous, contains lakes, wetlands or floodplains, all influence how a watershed responds to logging. "You should not be logging in one part of a watershed without accounting for what's happening elsewhere in the same drainage basin," he said. "Water flows from highlands to lowlands so we need cumulative impact studies before moving ahead with forest development." Alila says the current regulations in B.C. don't require companies to conduct proper watershed-level impact assessments before logging. Researchers say the study's findings are directly relevant to the province, where clear-cut logging remains common and terrain features mirror those of the test site. "Clear-cut logging in B.C. has increased the downstream flood risk rather dramatically," Alila added. He points to the devastating 2018 floods in Grand Forks, B.C. as an example, saying clear-cutting in the Kettle River watershed played a major role. Most flood models that predict the behaviour of floodwaters, assume a simple, predictable relationship between logging and flooding, the UBC professor says. For example, cutting down X per cent of trees, will likely result in Y per cent more water runoff. But the study says after clear-cutting, the risk of extreme and unpredictable floods increases in ways that these basic models can't capture. "This experimental evidence validates our longstanding call for better analysis methods," said Alila. "When we apply proper probabilistic tools to long-term data, we find much stronger and more variable impacts than older models suggest." Jens Wieting, senior policy and science advisor with Sierra Club B.C., said the study underscores the need to reform forestry practices to respond to climate risks. "This study is really demonstrating that we need a precautionary approach," said Wieting. "Clear-cutting can make climate change impacts worse." He said moving away from clear-cutting and toward selective logging — a practice where only certain trees are harvested, leaving the rest of the forest intact — could help reduce flood risk, restore degraded landscapes, and save money in the long run by avoiding climate disaster costs. Province acknowledges research In a statement to CBC News, the B.C. Ministry of Forests said it "appreciates the research being done at UBC" and emphasized that the province continues to invest in water and forest management. "Currently, through allowable cut determinations, the Chief Forester places limits on the rate of cut in each watershed to help provide balance to the many values our forested landscapes provide, including reducing flood risks," the statement reads. The ministry says it's also moving beyond traditional modelling to better understand how changes to forests, water, and climate affect long-term sustainability. That includes promoting practices like selective thinning, fuel management and forest restoration. The province has also introduced Forest Landscape Planning (FLP), which it describes as one of the most effective tools for reducing flood risk at a broader scale. Still, Alila says implementation of old-growth deferrals and other reforms from the province have been slow.